- Home
- ICCC
ICCC
ImmuCell Corporation
as 11-21-2024 4:00pm EST
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | PORTLAND |
| Market Cap: | 28.0M | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 14.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.34 - $5.59 | Next Earning Date: | 11-13-2024 |
| Revenue: | $23,838,002 | Revenue Growth: | 46.37% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ImmuCell Corporation News
ICCC Breaking Stock News: Dive into ICCC Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
Simply Wall St.
5 days ago
ImmuCell Third Quarter 2024 Earnings: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023)
GlobeNewswire
8 days ago
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
GlobeNewswire
14 days ago
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
GlobeNewswire
a month ago
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
Simply Wall St.
3 months ago
ImmuCell Second Quarter 2024 Earnings: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023)
GlobeNewswire
3 months ago
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
GlobeNewswire
3 months ago
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
Compare ICCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICCC ImmuCell Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.